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Abstract The Patient Protection and Affordable Care Act,
signed into law in 2010, will have a wide-reaching impact on
the health care system in the United States when it is fully
implemented in 2014. Patients will see increased access to
care coupled with new insurance coverage protections as well
as a minimum set of benefits mandated in each state known as
essential health benefits. Providers are likely to see new forms
of payment reform, particularly in the Medicare program, and
narrower commercial provider networks. In addition, the com-
position of the health insurance market will broaden with the
introduction of health insurance exchanges and expanded
Medicaid populations in many states. Furthermore, the Patient
Protection and Affordable Care Act calls for quality initiatives
such as comparative effectiveness research to increase effec-
tive, appropriate and high-value care. This paper will review
the main provisions of the Patient Protection and Affordable
Care Act with specific attention to their impact on the field of
Stem Cell Transplantation.
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Introduction
The Patient Protection and Affordable Care Act [1], known as
the ACA, was signed into law on 23 March 2010. The law is
intended to increase access to health care while reducing the
overall cost of health care. On the whole, patients who have
had or who will need a stem cell transplant should benefit
from expanded access to affordable insurance options and the
removal of long-standing benefit and coverage restrictions as
provided under the ACA. However, there remains significant
room within the law that raises other concerns regarding
access that will need to be monitored for potential impact to
patients and providers. In this article, we will explore specific
sections of the ACA and their potential impact on patients and
providers. We will suggest ways in which the provider com-
munity may want to respond to the new challenges and
opportunities presented by the law in order to best serve
themselves and their patients.
Implementation
The provisions of the ACA are phased in over a period of time
to allow stakeholders time to prepare. While a number of
provisions have already been implemented, those changes that
significantly expand access to health care or modify insurance
coverage requirements go into effect on 1 January 2014.
These include, among many others, expanded Medicaid cov-
erage, access to insurance marketplaces through state and
federal healthcare insurance exchanges and the elimination
of insurance provisions such as annual and lifetime maximum
benefit dollar amount limits.
Efforts to reduce the cost of healthcare are also being
phased in. These initiatives create incentives for healthcare
payors (health plans, employers and other purchasers) and
providers to pursue quality improvement strategies together.
The goal is to achieve efficiencies in the delivery of healthcare
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by reducing administrative costs, mandating the use of quality
measure reporting, focusing on delivering appropriate care
and by using comparative effectiveness studies to better define
and guide patients to the most appropriate care.
Physicians and the patients they treat are anxious to under-
stand the impact of this legislation as it is being implemented
[2]. Some components, such as the Medicaid expansion, are
fairly well established, but as for the definition of benefits and
provider networks available through the exchanges, they are
still coming into focus. The exchanges opened to consumers
on 1 October 2013, and the offerings are being analyzed by
many interested parties, including the National MarrowDonor
Program (NMDP).
Stem Cell Transplant: Unique Areas of Concern
Stem Cell Transplantation (SCT) is a resource-intensive ther-
apy for critically ill patients with hematologic malignancies
and other illnesses. These patients need intensive, and fre-
quently expensive, treatment regimens both prior to and after
transplant. Patients who receive a SCTcontinue to need access
to specialized providers and treatment for the remainder of
their lives. The severity of illness in patients in need of a
transplant, as well as the transplant process and recovery
period, almost always leads to a period of time in which a
patient is absent from the workplace. This often results in
marked decrease in income during a period of increased
medical expenditures, as well as potentially jeopardizing the
individual’s ability to maintain his or her health insurance
coverage under typical insurances plans in existence today.
For years after the SCT, patients routinely face high out-of-
pocket spending because of on-going follow-up care, lab
testing and prescription drugs.
Prior to the enactment and implementations of the ACA,
SCT patients seeking new insurance coverage in the individ-
ual marketplace historically faced the potential of a lack of
insurers willing to insure them or limited benefit insurance
plans with prohibitively high premiums and pre-existing con-
dition exclusions of any costs related to the transplant.
The forthcoming changes to the health care and insurance
systems will positively impact SCT patients more quickly and
to a greater degree than an average health care consumer. We
will highlight how certain provisions will impact current or
former SCT patients throughout this discussion.
Expanding Access to Healthcare
A primary goal of the ACA is to reduce the number of
uninsured Americans. The ACA increases access to health
insurance through three primary avenues. First, it requires
existing insurance coverage, such as through employer pro-
vided health plans, to meet certain standards of coverage and
benefits. Second, it creates a mechanism, known as the
healthcare insurance exchanges, through which individuals
and small groups can compare and purchase health insurance
policies. Third, in states that elected to participate, it expands
the individual and family income limits that determine eligi-
bility for participation in a Medicaid program.
The drafters of the ACA understood that simply organizing
a market for insurance products would not likely compel all
potential enrollees to participate. Those without any known or
current health concerns may decide to wait until an issue
occurs and then subscribe. This would create adverse selection
where only those who have a known need for health insur-
ance, outside of preventive care, purchase it. This defeats the
goal of creating market based affordable health insurance as
there are no low-cost members to off-set the claims expenses
of high-cost members. Thus, the law provides that individuals
not otherwise covered underMedicare, Medicaid, or employer
provided health plans must purchase insurance coverage or
face a financial penalty. This assures the broadest base of
consumers against which the payors can price the products.
Further, the law limits segmentation of the market for pricing
purposes. Premium assistance subsidies based upon consumer
need as measured by individual or family income are also
provided under the ACA to assure all have the means to
acquire insurance through the exchanges.
Applicability of New Requirements
As noted, one of the goals of the ACA is to assure that all
individuals have insurance coverage. The law attempts to
preserve the existing private based insurance system that
covers most Americans, while bringing some consistency to
the benefits provided across all insurance products. However,
the law does not mandate complete uniformity, and leaves
room for changes over time in existing plans to move toward a
more common benefit set.
The private insurance market is defined by three main
categories through which consumers obtain coverage. The
first category is insurance provided to individual purchasers
who purchase the insurance as a single person or a person and
his/her dependents that purchase a policy directly from an
insurer. The second category is insurance acquired through
group purchasing, typically provided by employers. Groups
that are fully insured pay a monthly premium to a health
insurance company and the insurance company assumes all
risk – i.e., all responsibility for paying claims incurred by that
group, regardless if the cost total is more than the premiums
paid. The final category is coverage provided directly by an
employer who takes all risk in providing coverage, referred to
as self-insured or self-funded plans. Commonly, employers
with self-insured plans protect against financial risk through
another form of financial insurance, known as stop-loss insur-
ance, to protect against unforeseen individual or aggregate
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costs above an expected dollar amount. Self-insured groups
contract with claims administrators or health plans to handle
the administration of their health benefits and give them
access to a contracted provider network.
The ACA allows for the continuation of certain plans
currently in existence, known as “grandfathered” plans even
though they may not follow all of the requirements of the
ACA. Grandfathered plans are those that were purchased prior
to the law’s signing in 2010 and that have not made any
changes of specific types that dictate maintenance of this
status. Table 1 shows which ACA requirements apply to
grandfathered plans. The number of grandfathered plans is
expected to fall substantially over the next few years due to the
nature of the changes that most plans will need to make during
this time [3].
Due to the various mechanisms through which insurance
can be provided to employees and to the grandfathered/non-
grandfathered status issue, it will be very important that all
transplant programs review the individual benefits for each
patient. Very few assumptions can be made about the insur-
ance provision changes outlined in the following section.
Changes to Insurance Coverage and Benefit Provisions
The ACA assures access to health insurance in a number of
ways, particularly for those purchasing coverage through the
individual marketplace. The ACA creates “guaranteed issue”
requirements– meaning that anyone eligible for insurance
cannot be turned away – and prevents insurers from
rescinding coverage from someone when they are diagnosed
with an illness or condition. Lifetime dollar limits on total paid
benefits are no longer allowed after 1 January 2014. Annual
dollar limits are allowed only in a much more restricted
manner, specifically for services not covered by the definition
of the Essential Health Benefits, discussed below, or those
provided by a grandfathered plan.
The ACA also removes pre-existing condition exclusions.
This means that patients who have had a hematologic malig-
nancy or other significant health condition in the past cannot
be excluded from coverage or held responsible for medical
costs associated with those conditions in the future. This will
be particularly helpful to individuals who were pediatric SCT
patients and are now attempting to secure their own individual
coverage as an adult. Stem cell donors will also benefit,
because a history of donation cannot be used to deny them
purchasing an individual plan. Finally, since 2011, the ACA
required that health plans allow dependent children to stay on
their parents’ individual or group health plan until they are
26 years old. This is very useful for adolescent and young
adult SCT patients who want to maintain consistent coverage
and benefits at their original transplant center for an extended
period.
Another important requirement that will benefit SCT pa-
tients is the right that insured members have to an external,
independent review of a benefit or care denial by a health plan.
This provision has been in place since 2012 and mandates that
health insurance companies inform patients of the external
review process and whether a patient’s state has a Consumer
Assistance Program that could be of help during the appeal
review process. The expanded review process may be helpful
for patients pursuing transplant since many SCT patients face
denials on a variety of authorization requests, such as drug
regimens, follow-up care items, a second transplant or addi-
tional cell infusion, or a transplant for a relatively new treat-
ment indication. An area of concern for this provision is that
the credentials of the external reviewer are not spelled out.
When seeking an external review, patients and physicians
should consider making a specific request for evaluation by
a transplant physician or hematology/oncology specialist.
Essential Health Benefits
The ACA mandates that health plans available to consumers
offer a comprehensive set of benefits, referred to as the Es-
sential Health Benefits (EHB). The Federal regulations require
ten areas of care to be included in all non-grandfathered health
plans. The ten areas are (1) ambulatory patient services, (2)
emergency services, (3) hospitalization, (4) maternity and
newborn care, (5) mental health, (6) prescription drugs, (7)
rehabilitative (skill recovery) and habilitative (skill acquisi-
tion) services, (8) laboratory services, (9) preventative and
wellness services and (10) pediatric services. While there is
not a specific mention of SCT as an EHB at the Federal level,
the components of the transplant process all fall into covered
categories.
In developing the benefit requirements in state exchanges,
states are not limited to the EHB set detailed by Health and
Human Services (HHS), and many states have provided addi-
tional EHB requirements for plans being offered for purchase.
In 2013, the NMDP conducted an analysis of every state’s
EHB benchmark plan – the plan being used as a model for
others being offered through the exchange - looking for SCT
Table 1 Grandfathered Plans Description
Applies to Grandfathered Plans Does Not Apply to Grandfathered
Plans
Removal of Lifetime Limits Out-of-Pocket Maximum Limits
Prohibition of Coverage
Rescission
Coverage of Clinical Trial Routine
Costs
Coverage of Dependents up to
age 26





Waiting Period Limit of 90
Days
Compliance with a Metal Tier
Category
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benefits. Twenty-eight states have specifically mentioned var-
ious components of SCT benefits in their EHB benchmark
plan documents, providing additional reassurance for patients
and providers in those areas (Fig. 1). However, transplant
programs should note that there were no uniform modifica-
tions or improvements made to transplant-specific benefits.
Donor search, cell procurement, and travel and lodging ben-
efits will continue to be limited in most areas and problematic
for patients beginning the transplant process.
Clinical Trials Coverage
Clinical trials coverage is a very important category to SCT
patients and their providers. Under the ACA, coverage for
routine costs associated qualifying patients within an approved
clinical trial will be required beginning in January 2014. Rou-
tine costs are defined as all aspects of care outside of the
investigational drug, item or procedure itself. Clinical trials
must be approved or sponsored by the National Institutes of
Health (NIH), the Center for Disease Control and Prevention
(CDC), The Agency for Healthcare Research and Quality
(AHRQ), Centers for Medicare & Medicaid Services (CMS).
Trials may be any phase (I-IV) and must be conducted in
relation to the prevention, detection, or treatment of cancer or
other life-threatening disease or condition. The Blood and
Marrow Transplant Clinical Trials Network (BMT CTN) is
funded by two divisions at the NIH and, thus, its trials should
qualify for routine cost coverage. Transplant programs within a
National Cancer Institute (NCI) Designated Cancer Center may
also face reduced barriers to patient clinical trial participation
based on this provision. In cases where transplant itself is the
investigational item of interest – i.e., the transplant is being
investigated for a new indication - payment for the cells and
hospital stay may not be covered. The nuance of implementing
this provision will need to be monitored for expected impact on
SCT research. Grandfathered plans do not have to recognize the
ACA requirement for clinical trials coverage, so transplant
centers may want to build an additional coverage verification
step into their financial planning process. However, state laws
may separately require clinical trial coverage under certain
conditions.
Transplant centers will need to provide clear communica-
tion to payors regarding the qualification of the trial, the
eligibility of the patient, and the portions of the treatment plan
that are routine or investigational.
Health Insurance Marketplaces – The Exchanges
The creation of the state and federal online marketplaces,
known as Health Insurance Exchanges (exchanges) [1], is
intended to assure access to insurance for individuals who
do not purchase insurance directly from an insurer or who
have coverage through their employer. The exchanges simpli-
fy the process of identifying coverage options, assist in deter-
mining potential Medicaid eligibility and assess an individ-
ual’s premium subsidy qualification. The exchanges will pro-
vide consumers with a menu of private insurance options
available to them in their state categorized by insurer, premi-
um, out-of-pocket costs, deductible and provider network.
The number of plans offered and the composition of insurers
Fig. 1 Essential Health Benefit Benchmark Plans SCTAnalysis
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on the exchanges will vary greatly from state to state. Sixteen
states and the District of Columbia will be running their own
exchanges while twenty-seven have defaulted to a federally
facilitated exchange model. The remaining seven states will
partner with the federal government in running their exchange
with the goal of creating a state run exchange in the future.
In 2014, thirty-one states will also offer the option to enroll
in one of the plans available to Federal Employees known as
the Multi State Plan Program run through the federal Office of
Personnel Management. The benefits these plans offer trans-
plant patients will become increasingly important both as a de
facto benchmark and due to their direct applicability to a large
number of enrollees.
In order to make the plan offerings easily comparable for
consumers, all plans offered through an exchange have to
offer benefits that align with one of the “metal tiers” – bronze,
silver, gold or platinum. These metal categories align with
different estimated percentages (ranging from 60 % to 90 %)
of expected annual average costs of services incurred within
the EHB categories that will be paid for by the plans. Bronze
plans will have more affordable premiums, with more out-of-
pocket spending through variables such as deductibles, co-
pays and co-insurance. Platinum plans will likely have higher
premiums and less variable cost. Gold and platinum plans may
also havemore benefits outside of the EHB categories, such as
travel and lodging expenses during a transplant. SCT patients
should carefully investigate plan options and may consider
incurring a more expensive fixed monthly premium to mini-
mize fluctuation in out-of-pocket spending during a time of
limited family income. All of the plans face the same limits on
out-of-pocket maximum limits: $6,350 for an individual or
$12,700 for families [4].
The exchanges will be replacing state-run high-risk pools
(individual insurance pools for those with health conditions
who cannot access coverage otherwise) in most states. Many
SCT patients have participated in high-risk pools in the past
and may need assistance from their transplant center in eval-
uating their insurance options through the exchanges. Trans-
plant programs may want to review the plans available in their
local exchange for transplant-specific benefits and create a list
of plans with benefits that are supportive of the transplant
process [5].
Provider Networks in the Exchanges
Health insurance companies offering plans through the ex-
changes will likely have limited provider networks in order to
keep the premiums affordable and competitive. These limita-
tions in network size have the potential to create delays and
obstacles for patients trying to make appointments for the
evaluation of initial symptoms or with specialists for treatment
planning and follow-up care. An even greater concern is that
patients may sign on to a plan with a network that does not
offer all transplant options. For instance, in Minnesota at the
time of this writing, only nine of the thirteen plans available
through the state exchange have an allogeneic stem cell trans-
plant center in their provider network [6]. Whether patients
will be allowed access to out-of-network providers in cases of
specific transplant type or disease indication remains to be
seen. Transplant programs should research which Exchange
plans their facility is participating in and be prepared to
communicate this to current and future patients.
Medicaid Expansion
The ACA provided that all states must expand coverage under
Medicaid to individuals up to 133 % of the Federal Poverty
Level (FPL) and provided federal funding to cover the cost of
increased coverage. However, in 2012, the United States
Supreme Court declared that this requirement was unconsti-
tutional and that each state had the right to decide whether or
not to implement this provision of the ACA. As a result, the
extent of Medicaid coverage is to be determined on a state-by-
state basis. As of November 2013, twenty-five states have
elected to expand coverage and receive the associated federal
funding. Five other states are still considering expanding their
Medicaid programs in an effort to reduce their state insurance
coverage gaps. There is no deadline for expanding Medicaid
programs and many more states are expected to expand their
programs in the near future. Medicaid expansion is expected
to increase the number of enrollees from 48.3 million to 66.4
million [7]. States may determine if they will add the newly
eligible low-income adults to their current adult benefit pack-
age or if they will provide an alternative benefit package to
this group. The benefit package made available to the expan-
sion population is required to meet the EHB specifications as
determined by the state benchmark plan.
Expanded Medicaid will have both positive and negative
repercussions for patients and transplant programs. Increased
access to coverage will mean more patients have SCT as a
treatment option, but this expansion does not improve the
quality of benefits or the reimbursement rates associated with
state Medicaid plans. An increase in Medicaid patients with
these less-than-ideal coverage provisions will mean an in-
creased burden on already limited transplant center resources
[8]. Transplant centers in states with problematic Medicaid
coverage indications, benefits, or extremely low reimburse-
ment levels may want to consult with government policy staff
at their medical centers to develop an outreach plan to state
health officials.
Payment Reform
In addition to access, the other significant tenet of the ACA is
an overall reduction in healthcare spending, particularly in the
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Medicare program. The applicable provisions include penal-
ties for certain readmission types, stricter fraud and abuse
regulations, and incentives for the adoption and use of quality
measurements. Hospitals are facing additional payment
changes through reductions to Disproportionate Share Hospi-
tal (DSH) payments, graduate medical education spending
and reduced physician fee payments. These reductions are
intended to encourage providers to identify and utilize effi-
cient care practices while reducing unnecessary care [9].
Incentives are also provided to encourage the develop-
ment of Accountable Care Organizations (ACOs) and the
use of bundled payments. ACOs are designed to transfer
responsibility for management of healthcare services to
provider-based organizations that are provided funds to
manage the healthcare needs of a population rather than
payment for specific services. Bundled payments are de-
signed to extend current payment methodologies, such as
the Diagnosis Related Group (DRG) payments used in the
Inpatient Prospective Payment System (IPPS), over a
broader set of healthcare services around specific diagno-
ses. Under a bundled payment scheme, a single payment
may include professional services, facility payments and
aftercare arrangements. Groups of providers will be en-
couraged to work together to manage patients in a more
efficient and cost-effective manner.
As is the case with many of the provisions of the ACA, the
expected impact on transplant centers is uncertain. However, it
will likely be significant since Medicare eligible patients are
the fastest growing segment of allogeneic unrelated trans-
plants [10]. Transplant centers will be well-served by prepar-
ing for new models of payment bundling, pay-for-quality
programs and an increased focus on cost-effectiveness and
value from all payor types. Transplant centers will be under
pressure to document quality of care, measured by both spe-
cific elements of care provided to patients as well as outcomes,
to avoid penalization or earn incentives. In addition, while
transplant physicians and centers have historically worked
closely together to manage patient care, the development of
ACOs and bundled service arrangements may extend the
network of providers for which the transplant physician and
center will need to interact in the management of the patient
and the time frame over which the assigned payment will
extend. The transplant community needs to begin considering
how to best collect and identify true costs of care delivery and
how to communicate the value and cost-effectiveness of
transplantation.
An increased focus on quality initiatives is expected to
drive a decrease in spending by providing effective, appropri-
ate and high-value care. The ACA established the Patient-
Centered Outcomes Research Institute (PCORI) to identify
research priorities and sponsor comparative effectiveness re-
search on treatment options. Medicare will also be expanding
its physician quality measure reporting program to additional
specialties. SCT physicians interested in individual and team
outcome assessment should begin to identify quality measures
of potential interest.
Conclusion
The Affordable Care Act is ambitious, broad-reaching and
complex. There will be a significant amount of turmoil for
several years after the implementation of the 2014 require-
ments. Physicians and transplant centers will likely need to
assist patients with their navigation of the new Exchanges and
networks in order to access the specialized care they need.
Additional federal regulatory guidance is needed to clarify the
more complex ACA provisions and their interactions with our
health care system. Transplant centers should not assume that
patients understand this new healthcare world or that the
insurance benefits that providers were used to working with
are still applicable. Keeping up-to-date on key factors of the
ACA and how implementation is being handled by the states
in the transplant centers referral area will be crucial to provid-
ing relevant and comprehensive patient support.
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